In this review, we studied drug development in dementia with Lewy bodies by analyzing three international clinical trials registries

To date, 25 agents across 40 clinical trials have been investigated in dementia with Lewy bodies. More than half of the trials have been conducted in the last 10 years, with 9 remaining active

There is increased interest in disease-modifying therapies in dementia with Lewy bodies that currently represent 55.5% of ongoing clinical trials (5 studies)

Current challenges for dementia with Lewy bodies drug development include increased diagnosis at earlier stages of the disease, disease-specific outcome measures and biomarkers, augmenting global representation, and including more diverse populations